Proactive Investors - Run By Investors For Investors

VentriPoint Diagnostics bolsters expansion plans with new business advisory committee

Samuel Schwartz has been named as the BAC's inaugural chairman
doctor with patient
The firm's heart monitoring system allows clinicians to assess heart function

VentriPoint Diagnostics Ltd (CVE:VPT) has further bolstered its expansion plans, establishing a business advisory committee (BAC) and naming Samuel Schwartz as its inaugural chairman.

"We are very pleased to have Sam's many years of assisting small companies to grow internationally at our disposal," said Dr George Adams, chief executive at medtech firm Ventripoint.

"This is especially important at this time as the company looks at strategic approaches to growing its business."

"I am excited to have the opportunity to bring together a world-class group to advise Ventripoint on its goal to achieve better cardiac diagnosis and monitoring for everyone, especially children," said Dr Schwartz.

Schwartz was the managing partner of the Toronto office of DLA Piper Canada LLP, where he practised in many areas of the law, including corporate finance, structuring and securities law, and merchant banking.

His diverse clients included Canadian and foreign companies involved in the life sciences, biotech, computer hardware and software markets.

Last month, Ventripoint revealed it was among the top 50 performers on the TSX venture exchange over the last year, according to the exchange's ranking system.

The group has pioneered the VMSplus heart analysis device, and it (the company) has been added to the 2018 TSX Venture 50.

"2017 was a historical year for Ventripoint, our employees and shareholders, who have seen the company increase in market capitalisation by 384% and experience share price appreciation of 258%, while trading 206 million shares on the TSX Venture Exchange and 250mln shares on all share exchanges," said Dr Adams.

Its VMS Plus is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound.

The company has developed a suite of applications for all major heart diseases and is actively commercialising the approach to improve cardiac care.

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use